Microsoft finetuning anti-pandemic technologies in a ‘stimulating playground for algorithm development’

A university, health system and tech giant are piloting the use of deep learning with IoT and edge computing to block COVID-19 from infiltrating a 548-bed hospital.

Microsoft publicized the project Nov. 5, saying its work with seven-hospital Providence Health Care of Canada and computer vision researchers at the University of British Columbia will leverage the technology combo to safeguard patients, staff and visitors alike.

It will first do so by monitoring PPE, social distancing and occupancy at St. Paul’s Hospital in Vancouver.

“First rolled out in the hospital’s emergency and radiology waiting rooms, and laboratory services, the project is facilitated using cameras that detect face mask usage and social distancing levels with a goal of eventually scaling to hundreds of cameras within high-traffic areas,” Microsoft News Centre Canada reports.

The cameras don’t gather information that could be used to identify individuals, Microsoft says.

Helge Rhodin, a UBC computer scientist, tells Microsoft that AI-driven computer vision “has come a long way, yet reaching the levels required for robust and widespread deployment in an ever-changing real world still holds many open challenges. This joint project on handling the new normal yields a stimulating playground for algorithm development within a framework of privacy and ethical computing.”

Read the whole thing.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.